Cindy Huang, MD
Nephrology · Clinton, MDNPI 1013059054
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.4%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. Gilead accounts for 70.9% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2019 at $5,463 and has fallen 86.6% since, to $732 in 2025. Among nephrology clinicians in MD with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 56 payments — averaging $131.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$5K
- Bayer$640
- AstraZeneca$512
- Ardelyx, Inc.$347
- ARS Pharmaceuticals Operations, Inc.$100
- Mallinckrodt Enterprises LLC$95
- plus $446 from 9 others
What the payments were for
- Consulting fees$4,00054%
- Travel & lodging$1,03014%
- Food & beverage$2,21030%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 11 | $5,208 |
| Bayer | 15 | $640 |
| AstraZeneca(2 entities) | 4 | $512 |
| Ardelyx, Inc. | 10 | $347 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $100 |
| Mallinckrodt Enterprises LLC | 1 | $95 |
| Philips North America LLC | 1 | $94 |
| Calliditas Therapeutics US Inc. | 1 | $75 |
| Baxter Healthcare | 1 | $66 |
| Travere Therapeutics, Inc. | 4 | $66 |
| Otsuka America Pharmaceutical, Inc. | 3 | $55 |
| Boehringer Ingelheim | 1 | $26 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $26 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Novo Nordisk | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Vemlidy$5,024
- Kerendia$370
- FARXIGA$115
- XPHOZAH 30 MG$103
- NEFFY$100
How this compares
$7,349 in reported general payments places this provider in the 90th percentile of 285 nephrology providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 50 | $33,329 |
| ClinolipidFat Emulsion/Olive/Soy/Phospho | 52 | $14,043 |
| EliquisApixaban | 26 | $8,551 |
| RenvelaSevelamer Carbonate | 13 | $8,122 |
| EntrestoSacubitril/Valsartan | 14 | $4,797 |
| Sevelamer Carbonate | 26 | $3,614 |
| Labetalol Hcl | 36 | $1,062 |
| Levetiracetam | 21 | $808 |
| Nifedipine ErNifedipine | 17 | $710 |
| Amlodipine Besylate | 74 | $556 |
| Pravastatin Sodium | 21 | $549 |
| Levothyroxine Sodium | 33 | $524 |
| Divalproex Sodium | 12 | $485 |
| Atorvastatin Calcium | 26 | $427 |
| Midodrine Hcl | 18 | $334 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga | $512 | $33,32950 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 285 nephrology providers in Maryland.
Other nephrology in Clinton
- Marc BrazieClinton$7K
- Kiran SamindlaFrederick$491K
- Matthew WeirBaltimore$490K
- Chirag ParikhBaltimore$186K
- Mohamad HanounehBaltimore$174K
- Daniel BrennanBaltimore$133K
- Monika DhillonBaltimore$126K
- Duvuru GeethaBaltimore$91K
- Eli RozaHagerstown$79K
- Mohamed AttaBaltimore$65K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.